Humphrey Wong

Humphrey is an associate in the Corporate team of our Hong Kong office. His practice focuses on capital markets, corporate finance, mergers and acquisitions and general corporate compliance.

Experience

Representative matters

Advising Shanghai Fosun New Medicine Research Company Limited (“Fosun New Medicine”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code: 2196), in relation to its proposal for the pre-conditional privatisation of Shanghai Henlius Biotech, Inc. (“Henlius”, stock code: 2696) by Fosun New Medicine as an offeror by way of merger by absorption of Henlius. The proposal valued Henlius at HK$13.37 billion (US$1.71 billion).

Advising Palasino Holdings Limited (“Palasino”) (stock code: 2536), a leading European gaming and leisure group, on its HK$371 million (US$47 million) IPO on the Main Board of the Stock Exchange of Hong Kong. The listing constituted a spin-off of Palasino from Far East Consortium International Limited (stock code: 35).

Advising a joint venture formed by China City Gas (a wholly-owned subsidiary of China Gas Holdings Limited), Vantage Energy (a wholly-owned subsidiary of Wah Kwong Maritime Transport Holdings Limited) and Fortune Clean Energy (a wholly-owned subsidiary of CSSC (Hong Kong) Shipping Company Limited) for the construction of LNG carriers on its shareholders’ agreement and the formation of the JV to develop LNG-related business.